Date	e: April. 1 st , 2022		
You	r Name:Xiaolian Su		
Man	nuscript Title: Prelimina	ary study on assessment o	f early cartilage degeneration by quantitative ultrashort echo
time	e (UTE) MRI in vivo		
Man	nuscript number (if known):	QIMS-21-1181	
relate part to trelate	ted to the content of your n ies whose interests may be ansparency and does not no tionship/activity/interest, it	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current
to th		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is	· · · · · · · · · · · · · · · · · · ·	d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	√None	
		T: f	4.26 months
2	Grants or contracts from	Time frame: pas √ None	t 50 months
_	any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	√None	
4	Consulting fees	√ None	

5	Payment or honoraria for	√None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
7	Support for attending meetings and/or travel	✓ _None	
8	Patents planned, issued or pending	√ None	
9	Participation on a Data	_ √None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options		
12	Receipt of equipment,	/ Name	
12	materials, drugs, medical	√ None	
	writing, gifts or other		
	services		
13	Other financial or non-	√_None	
	financial interests		
	se summarize the above co	nflict of interest in the foll	owing box:

Date	e:April. 1 st , 2022_		
You	r Name: Yixuan Zhang		
Mar	nuscript Title: Prelimina	ary study on assessment o	f early cartilage degeneration by quantitative ultrashort echo
	e (UTE) MRI in vivo		
Mai	nuscript number (if known):	QIMS-21-1181	
rela part to to rela The mar The to	ted to the content of your naties whose interests may be ransparency and does not nationship/activity/interest, it following questions apply the truscript only. author's relationships/activity and the epidemiology of hypertedication, even if that medication.	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. It is preferable that you do to the author's relationship wities/interests should be g nsion, you should declare ation is not mentioned in the	os/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		·	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed) Time frame: Since the initia	al planning of the work
1	All support for the present		ar planning of the work
1	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	_√_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ √None	
4	Compulsion for		
4	Consulting fees	√ None	

5	Payment or honoraria for	_ \ldNone
	lectures, presentations, speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	√ None
	testimony	
7	Support for attending	√ _None
	meetings and/or travel	
8	Patents planned, issued or	√None
	pending	
9	Participation on a Data	√ None
	Safety Monitoring Board or Advisory Board	
10	·	
10	Leadership or fiduciary role in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	√_None
12	Receipt of equipment, materials, drugs, medical	√None
	writing, gifts or other	
	services	
13	Other financial or non-	√_None
	financial interests	
-		
Plea	ise summarize the above co	nflict of interest in the following box:
	lone.	
'`	one.	

Please place an "X" next to the following statement to indicate your agreement:

Dat	e:April. 1 st , 2022_		
You	r Name: Qiuming Gad		
			f early cartilage degeneration by quantitative ultrashort echo
	e (UTE) MRI in vivo		
Maı	nuscript number (if known):	QIMS-21-1181	
rela part to	ted to the content of your raties whose interests may be ransparency and does not notionship/activity/interest, in following questions apply thuscript only. author's relationships/activity author's relationships of hypertedication, even if that medication.	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. It is preferable that you do to the author's relationship wities/interests should be go nsion, you should declare ation is not mentioned in the	os/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed) Time frame: Since the initia	al planning of the work
1	All support for the present		in planning of the work
1	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ √None	
4	Consulting fees	/ N===	
4	Consulting ICCS	√ None	

5	Payment or honoraria for		
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_ √None	
	testimony		
-	Compant for attacking		
7	Support for attending meetings and/or travel	√ _None	
8	Patents planned, issued or pending		
9	Participation on a Data	_ √None	
	Safety Monitoring Board or		
_	Advisory Board		
10	Leadership or fiduciary role in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	_ √ _None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		
eماp	ase summarize the above co	nflict of interest in the foll	owing hox:
	ise sammanize the above to	milet of interest in the for	owing son.
N	lone.		

Please place an "X" next to the following statement to indicate your agreement:

Date	e:April. 1 st , 2022_		
You	r Name: Zonghui Liang		
Mar	nuscript Title: Prelimina	ary study on assessment o	f early cartilage degeneration by quantitative ultrashort echo
	e (UTE) MRI in vivo		
Mar	nuscript number (if known):	QIMS-21-1181	
rela part to to rela The mar The to to	ted to the content of your name ites whose interests may be cansparency and does not not item in the content of your name items in the your name items in the content of your name items in the yo	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do to the author's relationship vities/interests should be go nsion, you should declare tion is not mentioned in t	os/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is		d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	√_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√ _None	
4	Consulting fees	_√_None	

5	Payment or honoraria for	_ √None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	√ None	
	testimony		
	·		
7	Support for attending	√ _None	
	meetings and/or travel		
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data	_ √None	
	Safety Monitoring Board or Advisory Board		
10	·	,	
10	Leadership or fiduciary role in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√ None	
12	Receipt of equipment,		
	materials, drugs, medical		
	writing, gifts or other		
12	services		
13	Other financial or non- financial interests	√ None	
	illialiciai liiterests		
Plea	ise summarize the above co	nflict of interest in the following box:	
			_
N	one.		
			╛
Dloa	se place an "Y" poyt to the	following statement to indicate your agreement:	

Date	e:April. 1 st , 2022_		
	r Name: Lidi Wan		
			f early cartilage degeneration by quantitative ultrashort echo
time	(UTE) MRI in vivo		
Man	uscript number (if known):	QIMS-21-1181	
relate parte to trelate The man	ted to the content of your name ies whose interests may be cansparency and does not not ionship/activity/interest, it following questions apply touscript only.	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. is preferable that you do the author's relationship	relationships/activities/interests listed below that are any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current defined broadly. For example, if your manuscript pertains
to th		nsion, you should declare	all relationships with manufacturers of antihypertensive
	em #1 below, report all sup time frame for disclosure is	·	d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	√_None	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√ None	

5	Payment or honoraria for	√None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
7	Support for attending meetings and/or travel	√_None	
8	Patents planned, issued or pending	_ √None	
9	Participation on a Data	_ √None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
12	Receipt of equipment,	√_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	√ None	
	financial interests		
	one.	nflict of interest in the fol	owing box:
	ssa nlassa an "Y" novt to the	following statement to inc	licate vour agreement.

Date	e:April. 1 st , 2022_		
	r Name: Lin Zhang		
Man	uscript Title: Prelimina	ry study on assessment o	f early cartilage degeneration by quantitative ultrashort echo
time	e (UTE) MRI in vivo		
Man	uscript number (if known):	QIMS-21-1181	
relate parte to trelate	ted to the content of your n ies whose interests may be ansparency and does not no tionship/activity/interest, it	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current
The to th	author's relationships/activ	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is	·	d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	√ _None	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√ _None	
3	Royalties or licenses	√None	
4	Consulting fees	√ None	

5	Payment or honoraria for	√None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
7	Support for attending meetings and/or travel	√_None	
0	Data ata alama ad isawa da a	1	
8	Patents planned, issued or pending		
9	Participation on a Data		
9	Safety Monitoring Board or	_ √None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Possint of aguinment	/ N	
12	Receipt of equipment, materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		
	se summarize the above co	nflict of interest in the foll	owing box:
Plan	se place an "Y" nevt to the	following statement to inc	licate vour agreement:

Date	e:April. 1 st , 2022_		
	Name: Guangyu Tan		
Man	uscript Title: Prelimina	ary study on assessment of	early cartilage degeneration by quantitative ultrashort echo
	(UTE) MRI in vivo		
Man	uscript number (if known):	QIMS-21-1181	
relate part to trelate	ted to the content of your name ies whose interests may be ansparency and does not not ionship/activity/interest, it following questions apply t	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. it is preferable that you do	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of the manuscript about whether to list a so.
<u>man</u>	uscript only.		
to the med	ne epidemiology of hyperte ication, even if that medica	nsion, you should declare a tion is not mentioned in the port for the work reported	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript. In this manuscript without time limit. For all other items,
		None all autition with	Considerations (Comments
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses		
4	Consulting fees	_ √None	

5	Payment or honoraria for	√None
	lectures, presentations, speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	√None
	testimony	
7	Support for attending meetings and/or travel	\(\sqrt{None} \)
8	Patents planned, issued or pending	None
	F	
9	Participation on a Data	√ None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	√None
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	√ None
	, , , , , , , , , , , , , , , , , , ,	
12	Receipt of equipment,	√None
	materials, drugs, medical	
	writing, gifts or other	
13	services Other financial or non-	/ Name
13	financial interests	
	manda meereses	
Plea	ise summarize the above co	onflict of interest in the following box:
N	lone.	
Plpa	ise nlace an "X" nevt to the	following statement to indicate your agreement: